Rashid Nok Shun Lui

Dr. Rashid Nok Shun Lui

Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
SWSunny Wong
Sunny Wong
Rashid Nok Shun LuiRashid Nok Shun Lui
Rashid Nok Shun Lui
JSJoseph JY Sung
Joseph JY Sung
The novel coronavirus disease is currently causing a major pandemic. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a member of the Betacoronavirus genus that also includes the SARS‐CoV and Middle East respiratory syndrome coronavirus. While patients typically present with fever and a respiratory illness, some patients also report gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain. Studies have identified the SARS‐CoV‐2 RNA in stool specimens of infected patients, and its viral receptor angiotensin converting enzyme 2 was found to be highly expressed in gastrointestinal epithelial cells. These suggest that SARS‐CoV‐2 can actively infect and replicate in the gastrointestinal tract. This has important implications to the disease management, transmission, and infection control. In this article, we review the important gastrointestinal aspects of the disease.

2 April 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
JLJames Y.W. Lau
James Y.W. Lau
YYYuanyuan Yu
Yuanyuan Yu
RTRaymond S.Y. Tang
Raymond S.Y. Tang
HCHeyson C.H. Chan
Heyson C.H. Chan
HYHon-Chi Yip
Hon-Chi Yip
JSJoseph JY Sung
Joseph JY Sung
It is recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation. The role of endoscopy performed within time frames shorter than 24 hours has not been adequately defined.

24 May 2017 in Gut
Verified
Journal Article
Open access
PDF file
TZTao Zuo
Tao Zuo
SWSunny H Wong
Sunny H Wong
KLKelvin Lam
Kelvin Lam
Rashid Nok Shun LuiRashid Nok Shun Lui
Rashid Nok Shun Lui
KCKitty Cheung
Kitty Cheung
SNSiew C Ng
Siew C Ng
Objective: Faecal microbiota transplantation (FMT) is effective for the treatment of recurrent Clostridium difficile infection (CDI). Studies have shown bacterial colonisation after FMT, but data on viral alterations in CDI are scarce. We investigated enteric virome alterations in CDI and the association between viral transfer and clinical outcome in patients with CDI. Design: Ultra-deep metagenomic sequencing of virus-like particle preparations and bacterial 16S rRNA sequencing were performed on stool samples from 24 subjects with CDI and 20 healthy controls. We longitudinally assessed the virome and bacterial microbiome changes in nine CDI subjects treated with FMT and five treated with vancomycin. Enteric virome alterations were assessed in association with treatment response. Results: Subjects with CDI demonstrated a significantly higher abundance of bacteriophage Caudovirales and a lower Caudovirales diversity, richness and evenness compared with healthy household controls. Significant correlations were observed between bacterial families Proteobacteria, Actinobacteria and Caudovirales taxa in CDI. FMT treatment resulted in a significant decrease in the abundance of Caudovirales in CDI. Cure after FMT was observed when donor-derived Caudovirales contigs occupied a larger fraction of the enteric virome in the recipients (p=0.024). In treatment responders, FMT was associated with alterations in the virome and the bacterial microbiome, while vancomycin treatment led to alterations in the bacterial community alone. Conclusions: In a preliminary study, CDI is characterised by enteric virome dysbiosis. Treatment response in FMT was associated with a high colonisation level of donor-derived Caudovirales taxa in the recipient. Caudovirales bacteriophages may play a role in the efficacy of FMT in CDI. Trial registration number: NCT02570477

10 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Tao ZuoTao Zuo
Tao Zuo
SWSunny H. Wong
Sunny H. Wong
CCChun Pan Cheung
Chun Pan Cheung
KLKelvin Lam
Kelvin Lam
Rashid Nok Shun LuiRashid Nok Shun Lui
Rashid Nok Shun Lui
SNSiew C Ng
Siew C Ng
Fecal microbiota transplantation (FMT) is effective in treating recurrent Clostridium difficile infection (CDI). Bacterial colonization in recipients after FMT has been studied, but little is known about the role of the gut fungal community, or mycobiota. Here, we show evidence of gut fungal dysbiosis in CDI, and that donor-derived fungal colonization in recipients is associated with FMT response. CDI is accompanied by over-representation of Candida albicans and decreased fungal diversity, richness, and evenness. Cure after FMT is associated with increased colonization of donor-derived fungal taxa in recipients. Recipients of successful FMT (“responders”) display, after FMT, a high relative abundance of Saccharomyces and Aspergillus, whereas “nonresponders” and individuals treated with antibiotics display a dominant presence of Candida. High abundance of C. albicans in donor stool also correlates with reduced FMT efficacy. Furthermore, C. albicans reduces FMT efficacy in a mouse model of CDI, while antifungal treatment reestablishes its efficacy, supporting a potential causal relationship between gut fungal dysbiosis and FMT outcome.

7 March 2021 in Gut
Verified
Journal Article
Closed access
PDF file
SNSiew C Ng
Siew C Ng
ZXZhilu Xu
Zhilu Xu
JMJoyce Wing Yan Mak
Joyce Wing Yan Mak
KYKeli Yang
Keli Yang
QLQin Liu
Qin Liu
Francis Ka Leung ChanFrancis Ka Leung Chan
Francis Ka Leung Chan
Objective: The impact of faecal microbiota transplantation (FMT) on microbiota engraftment in patients with metabolic syndrome is uncertain. We aimed to study whether combining FMT with lifestyle modification could enhance the engraftment of favourable microbiota in obese patients with type 2 diabetes mellitus (T2DM).Design: In this double-blind, randomised, placebo-controlled trial, 61 obese subjects with T2DM were randomly assigned to three parallel groups: FMT plus lifestyle intervention (LSI), FMT alone, or sham transplantation plus LSI every 4 weeks for up to week 12. FMT solution was prepared from six healthy lean donors. Faecal metagenomic sequencing was performed at baseline, weeks 4, 16 and 24. The primary outcome was the proportion of subjects acquiring ≥20% of microbiota from lean donors at week 24.Results: Proportions of subjects acquiring ≥20% of lean-associated microbiota at week 24 were 100%, 88.2% and 22% in the FMT plus LSI, FMT alone, and sham plus LSI groups, respectively (p<0.0001). Repeated FMTs significantly increased the engraftment of lean-associated microbiota (p<0.05). FMT with or without LSI increased butyrate-producing bacteria. Combining LSI and FMT led to increase in Bifidobacterium and Lactobacillus compared with FMT alone (p<0.05). FMT plus LSI group had reduced total and low-density lipoprotein cholesterol and liver stiffness at week 24 compared with baseline (p<0.05).Conclusion: Repeated FMTs enhance the level and duration of microbiota engraftment in obese patients with T2DM. Combining lifestyle intervention with FMT led to more favourable changes in recipients’ microbiota and improvement in lipid profile and liver stiffness.Trial registration number: NCT03127696.

15 August 2024 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
LMLung-Yi Loey Mak
Lung-Yi Loey Mak
KLKen Liu
Ken Liu
SCSakkarin Chirapongsathorn
Sakkarin Chirapongsathorn
KYKuo Chao Yew
Kuo Chao Yew
NTNobuharu Tamaki
Nobuharu Tamaki
DHDaniel Huang
Daniel Huang